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a b s t r a c t
Inference on disease dynamics is typically performed using case reporting time series of symptomatic
disease. The inferred dynamics will vary depending on the reporting patterns and surveillance system for
the disease in question, and the inference will miss mild or underreported epidemics. To eliminate the
variation introduced by differing reporting patterns and to capture asymptomatic or subclinical infection,
inferential methods can be applied to serological data sets instead of case reporting data. To reconstruct
complete disease dynamics, one would need to collect a serological time series. In the statistical analysis
presentedhere,we consider a particular kind of serological time serieswith repeated, periodic collections
of population-representative serum. We refer to this study design as a serial seroepidemiology (SSE)
design, and we base the analysis on our epidemiological knowledge of inﬂuenza. We consider a study
duration of three to four years, during which a single antigenic type of inﬂuenza would be circulating,
and we evaluate our ability to reconstruct disease dynamics based on serological data alone. We show
that the processes of reinfection, antibody generation, and antibody waning confound each other and
are not always statistically identiﬁable, especially when dynamics resemble a non-oscillating endemic
equilibrium behavior. We introduce some constraints to partially resolve this confounding, and we show
that transmission rates and basic reproduction numbers can be accurately estimated in SSE study designs.
Seasonal forcing ismore difﬁcult to identify as serology-based studies only detect oscillations in antibody
titers of recovered individuals, and theseoscillations are typicallyweaker than thoseobserved for infected
individuals. To accurately estimate the magnitude and timing of seasonal forcing, serum samples should
be collected every two months and 200 or more samples should be included in each collection; this
sample size estimate is sensitive to the antibody waning rate and the assumed level of seasonal forcing.
ublis© 2015 The Authors. P
. Introduction
Analyzing time series of infectious disease case reports is the
ost common way to gain an understanding of disease dynamics.
ne advantage of this approach is that time series from hospi-
al reporting, community reporting, and sentinel surveillance are
eadily available. Because some surveillance systems have been
unning for decades, this is a good way to investigate the long-
erm dynamics of many diseases. Two drawbacks of this approach
re that it only counts symptomatic and reported cases, and that
eportingpatternswill varyacross studies andsites so that two time
eries will usually not be directly comparable. One way of circum-
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rust Major Overseas Programme, 764 Vo Van Kiet Street, District 5, Ho Chi Minh
ity, Viet Nam. Tel.: +84 83 923 7954; fax: +84 83 923 8904.
E-mail address: mboni@oucru.org (M.F. Boni).
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755-4365/© 2015 The Authors. Published by Elsevier B.V. This is an open access article uhed by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
venting these drawbacks and still capturing general-population
disease dynamics is to base a study on serology rather than symp-
toms and reporting patterns. A cross-sectional seroepidemiology
study will give us details on past dynamics if we assume (i) that
the infection process is independent of age, and (ii) that immunity
is lifelong (Grenfell and Anderson, 1985; Ferguson et al., 1999), but
the inferred dynamics will be coarsely broken up by year, unless
individuals’ ages are speciﬁed to one or two decimal places. How-
ever, if consecutive cross-sectional studies are performed, general
population incidence can be measured from any pair of consec-
utive cross-sectional collections, and long-term dynamics can be
analyzed for the duration that repetitive cross-sectional samples
are being collected.
In this paper, we analyze the usefulness of a serial seroepidemi-
ology (SSE) study design, which we deﬁne as a study consisting
of periodic collections of cross-sectional population-representative
serum samples. We base our analysis on inﬂuenza virus, although
the concepts are readily applied to other acute infectious diseases.
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tudies resembling SSE study designs have been carried out with
wo or three serum collections (Baguelin et al., 2011; Iwatsuki-
orimoto et al., 2011; McLeish et al., 2011; Soh et al., 2012; Yang
t al., 2012), with continuous serum collection (Wu et al., 2011,
014), and in southern Vietnam with long-term periodic collec-
ions (Boni et al., 2013; Todd et al., 2014). In this study, we analyze
he power of such a study to infer the basic reproductive number
f a pathogen as well as the timing and strength of its seasonal
ynamics. We describe certain parts of the dynamical process that
ay not be identiﬁable under various conditions. We show that
ertain intuitive assumptions about disease dynamics need to be
evisited when dynamical inference is based on serological data,
he reason being that observations in an SSE study are made on
ecovered/susceptible individuals instead of infected individuals.
he dynamics of recovered individuals are not normally studied
n detail, but when viewing serological time series, it is these
ynamics that provide the necessary information to reconstruct
ast epidemic dynamics. We show that accurate measurement of
heantibodywaningprocess is critical for inference inotherparts of
he system, and we present a power analysis showing how the epi-
emiological scenario, duration of the study, and the sample size of
ach collection affect likelihood-based statistical inference in this
ystem.
. Model and inference
We deﬁne a serial seroepidemiology study design as one in
hich N cross-sectional serum samples are collected every M
onths from the general population, or a pool of blood donors,
atients, or other individuals who may be representative of the
eneral population. Serum collections like these would in gen-
ral be age-stratiﬁed, but we do not take advantage of the age
nformation in the analysis presented here. We will base the anal-
sis that follows on inﬂuenza serology, although easy parallels are
rawn for other diseases, and we will assume that serum sam-
les are analyzed via haemagglutination inhibition (HI) assays or
icroneutralization (MN) tests to a single virus or antigen. These
ilution-based assays typically yield one of nine possible titer mea-
urements, ranging from 10 to 2560 by two-fold increases, with
560 corresponding to the highest measurable level of antibody in
sample and 10 corresponding to the lowest detectable level; we
lso include a class “<10” for undetectable antibody. Different dilu-
ion series are used sometimes, and the model structure is easily
odiﬁable to take this into account.
The purpose of the analysis is to reconstruct the disease dynam-
cs during the time that serum samples are being collected.
ormally such dynamics would be inferred by ﬁtting a dynamical
odel toa timeseriesof symptomatic andreportedcasesofdisease,
nd the statistical procedure would infer a reporting parameter
escribing the fraction of cases that are reported to a surveillance
ystem. When using cross-sectional serum samples from an SSE, it
s not necessary to infer a reporting parameter as the sample collec-
ions are believed to be representative of the population as awhole.
n this way, an SSE study will infer the complete disease dynamics
f all symptomatic and asymptomatic infections, as opposed to a
tudybasedoncase reportingwhichwill bias the inferreddynamics
o the dynamics of symptomatic and/or reported cases only.
.1. General dynamical model
In building a general dynamical model for inference in an SSE,
t is important to remember that the observed variables are recov-
red individuals, and not infected individuals. Therefore, themodel
tructure should include the observed variation in recovered indi-
iduals asmeasuredbyan immunological assay suchas anHI test orics 12 (2015) 30–39 31
aMN test, andwe achieve this by including ten separate population
classes for recovered individuals, R1 through R10. Many variations
of such models have been studied in the past (Hethcote et al., 1981;
Thieme and Yang, 2002; King et al., 2008). The speciﬁc dynamical
equations we use are:
E˙ = (t)
10∑
i=1
(1 − εi)Ri − hE
I˙ = hE − I
P˙ = I − P
R˙1 = p1P − (t)(1 − ε1)R1 − 1R1
R˙i = piP + i−1Ri−1 − (t)(1 − εi)Ri − iRi for 2 ≤ i ≤ 9
R˙10 = p10P + 9R9 − (t)(1 − ε10)R10
(1)
with a seasonal force of infection
 (t) = ˇ
(
1 + Acos+
(
2t
365
+ ϕ
))
I ,
where cos + refers to the non-negative part of the cosine function.
The host compartments in the model are exposed individuals (E),
infected individuals (I), recovered individuals who have not yet
mounted a full antibody response (P), and recovered individuals
whose speciﬁc antibody levels would give a result i in an immuno-
logical assay (Ri). For example, hosts in classes R8 and R9 would
have test outcomes of 20 and 10, respectively, in HI or MN assays,
and these hosts are considered to be almost fully susceptible.
It is important to note that when applying this model to
inﬂuenza epidemiology, the model is only valid for one antigenic
type (Smith et al., 2004). For collections over the past few years,
it would be assumed that individuals were infected with either
the original 2009 H1N1 pandemic strain (A/California/7/2009)
or an H3N2 strain similar to the A/Victoria/361/2011-like or
A/Texas/50/2012-like viruses. To use a model like this for analy-
sis of a longer-term data set (>10 years), two types of antibody
waning would need to be accounted for. The ﬁrst is the natural
waning of antibody levels that we have included in Eq. (1). The sec-
ond is the antibody waning that occurs as a result of antigenic drift
in the virus. As an example, an individual classiﬁed as R7 (HI titer
of 40) may have his or her neutralizing antibodies “wane” to class
R8 or R9 if an antigenically novel virus enters the population. For
the remainder of the analysis, we assume that there is only one
antigenic type.
Model parameters have the expected interpretations as in
standard epidemiological models (see Table 1). The parameters i
describe the process of antibody waning after the initial immune
response. The parameters pi sum to one, and describe the distri-
bution of antibody measurements expected shortly after a host
recovers from infection. The parameters εi fall between zero and
one, anddescribe thedegree towhichahost is protected from infec-
tion based on that host’s current immune status or antibody level;
note that we will have εi ≥ εj for i< j. See Fig. 1 for a class diagram
of the model.
Very few studies exist describing a complete antibody waning
process for an infectious disease. For inﬂuenza, it is believed that
the longest-lived antibody responses are those generated by infec-
tions experienced during childhood, a phenomenon that is referred
to as original antigenic sin (Fazekas De et al., 1966; Lessler et al.,
2012), and that these antibody responses are detectable at high lev-
els for decades (Yu et al., 2008). The longevity of antibody responses
to “non-original” infections is known less well, although our best
guess is that that antibody titers stay above the commonly used
threshold HI titer of 40 for years (Horsfall, 1940; Grilli et al., 1986;
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F fected
a strain
S
m
a
a
w
d
a
t
f
N
o
i
T
M
(
wig. 1. Class diagram for model (1). Population classes are exposed individuals (E), in
ntibody response (P), and recovered individuals with antibody titer i (Ri). Using con
everson et al., 2012; Ng et al., 2013), as opposed to decades or
onths. This is likely to depend on strain, age, the degree to which
virus cross-reacts immunologicallywith other circulating viruses,
nd whether the estimates come from vaccinees or individuals
ho were naturally infected. There is much less data on antibody
ynamics in the months following an infection, but Horsfall (1940)
ndHorsfall andRickard (1941) showed in a small group of patients
hat antibody concentrations fall between 1.0 and 1.5 units on a 2-
old dilution scale in the ninety days following infection; similarly
g et al. (2013) show a two-fold decline in antibody concentrations
ccurring after 100–200 days, depending on vaccination status and
nﬂuenza type.
able 1
odel parameters.
Parameter Description Value/range
ˇ Transmission parameter 0.25≤ˇ ≤0.45
A Amplitude of seasonal forcing function 0.1, 0.2
ϕ Phase parameter; timing of peak
transmission

−1 Infection duration 5 days
h−1 Incubation period 3 days
−1 Number of days post-infection before
antibody response is generated
14 days
pi Probability of immediate
post-infection titer of Ri
(*)
εi Susceptibility reduction (i.e. level of
protection) for hosts in Ri
(*)
i Antibody waning rate from Ri to Ri+1 (*)
	 Parameter for post-infection titer
distribution, deﬁned by (2)
0.2, 2.0, 20.0

 Susceptibility reduction parameter,
deﬁned by (3)
0.4≤
 ≤2.0
w Duration of antibody waning from
class R1 to R2
50 days
c Inﬂation parameter describing how
antibody waning slows down
0.2≤ c≤0.7
as Individuals move from Ri to Ri+1 to
Ri+2, etc.
e Probability that a serum sample is
misclassiﬁed with an error of one
two-fold dilution
0.05
*) In general, these parameters can vary freely, but normally we constrain them
ith Eqs. (2)–(4)individuals (I), recently recovered individuals who have not yet mounted a speciﬁc
ts (2) and (3), hosts inside the dashed box are completely refractory to reinfection.
One notable feature of many seroepidemiological studies is that
there are typically very few individuals in the highest titer classes
(e.g. 2560, 1280, 640), even when samples are taken soon after a
pandemic or epidemic wave (Miller et al., 2010; Deng et al., 2010;
Iwatsuki-Horimoto et al., 2011; Lessler et al., 2011; Dudareva et al.,
2011; Bone et al., 2012; Cauchemez et al., 2012). There are several
possible reasons for this. One is that individuals who seroconvert
to high titers do not sustain high titers for a long time. A second
reason is that seroconverters frequently seroconvert to the inter-
mediate titer classes (e.g. 160, 80, 40) without passing through the
high titer classes (Chen et al., 2010; Cauchemez et al., 2012). For
the purposes of this study, we assume that both of these processes
occur to varying degrees, parameterized by pi and i.
A major challenge in the analysis will be obtaining estimates of
antibody waning (i), partial immunity (εi), and the post-infection
titer distribution (pi). In order to reduce the degrees of freedom
in these parameters, we introduce some constraints. For hosts
recovering from infection, we assume that their immediate post-
infection titer distribution will be a truncated Poisson distribution
pi = C0e−	
	i−1
(i − 1)! for 1 ≤ i ≤ 4
pi = 0 for i > 4 (2)
where C0 is a normalization constant. This constraint allows us
to weight the post-infection titer distribution to the higher titers
or the middle titers with a single parameter 	. The three 	 val-
ues we will use for sensitivity analysis are 	=0.2 (approximately
82% of hosts would enter R1 after infection), 	=2.0 (an approxi-
mately uniform distribution of post-infection titers), and 	=20.0
(approximately 86% of hosts would enter R4 after infection).
Reduced susceptibility is modeled via
1 − εi = 0 for 1 ≤ i ≤ 4
1 − εi = 2((i−4)/6)

 − 1 for i > 4 (3)This parametrization with 
 allows susceptibility to increase from
0 to 1 as individuals pass through the R-classes (see Fig. 2). The
D.N. Vinh, M.F. Boni / Epidemics 12 (2015) 30–39 33
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rig. 2. (A) Susceptibility reduction (εi) in the different R-classes. Three values of 
 a
ight the ﬁve lines are for c=0.2, 0.4, 0.53, 0.625, 0.7.
lausible range of this parameter is 
 ∈ [0.4, 2.0]. For 
 =0.4, the
usceptibility reduction of hosts in R5 is 60%. For, 
 =2.0, the sus-
eptibility reduction in R5 is 98%, and the susceptibility reduction
n R8 is approximately 64%. The default value that we use is 
 =0.6,
hich corresponds to a 42% susceptibility reduction for hosts in R7
HI titer of 40) which is consistent with measurements obtained
rom inﬂuenza cohort studies, although it should be noted that
here is substantial variation in thesemeasurements (Hobson et al.,
972; Potter and Oxford, 1979; Couch et al., 2012; Ng et al., 2013;
sang et al., 2014). The classes R1–R4 are completely refractory
o infection, consistent with assumptions in previous models that
ecovered individuals cannot be immediately reinfected (Ferguson
t al., 2003; Tria et al., 2005; Minayev and Ferguson, 2009; Bedford
t al., 2012).
Antibody waning will be parameterized by c and w using
−1
i
= w · (1 + c)i−1 for 1 ≤ i ≤ 9 (4)
s the duration of time that a host spends in class Ri. The param-
ters c and w will be constrained to reﬂect the fact that the rate
f antibody waning in very immune individuals is faster than in
ess immune individuals. The parameter w in this situation is the
umber of days an individual stays in the R1 class after recover-
ng. Plausible ranges for these parameters are c ∈ [0.2, 0.9] and
∈ [20,90].
.2. Reduced dynamical model
One of our goals is to evaluate our ability to estimate the param-
ters 	, 
 , w, and c from SSE data. The limited number of serum
ampleswewouldexpect to see in thehigh-titer classes (R1 through
4)maymake it impossible to estimate the parameter	. To obviate
his problem, we use a reduced model that collapses classes R1–R4
nto a single population class R(1,4) which heuristically corresponds
o recently infected individuals. The dynamical equations for the
educed model are
E˙ = (t)
∑
i>4
(1 − εi)Ri − hE
I˙ = hE − I
P˙ = I − P
R˙(1,4) = P − (1,4)R(1,4)
˙
(5)R5 = (1,4)R(1,4) − (t)(1 − ε5)R5 − 5R5
R˙i = i−1Ri−1 − (t)(1 − εi)Ri − iRi for 6 ≤ i ≤ 9
R˙10 = 9R9 − (t)(1 − ε10)R10wn. (B) Five different antibody waning rates explored in this analysis. From left to
The constraints (2)–(4) are used to reduce the dimensionality of
parameter space. The parameter (1,4) is deﬁned as
−1(1,4) =
4∑
j=1
pj
4∑
i=j
−1
i
, (6)
and thus still depends on 	, but model dynamics are not very sen-
sitive to 	.
2.3. Likelihood framework
To determine how easily one can infer the epidemiological
and immunological parameters in systems (1)–(5), with or with-
out the constraints (2)–(4), we deﬁne a likelihood framework that
describes the probabilities of sampling recovered individuals with
particular antibody titers. We deﬁne an error function that allows
a serum sample to be misclassiﬁed one titer class higher or lower
with probability e; a serum sample is correctly classiﬁedwith prob-
ability 1−2e. Individuals sampled from classes R1 and R10 can only
be misclassiﬁed into one neighboring titer class with probability e,
and are correctly classiﬁed with probability 1− e. Individuals sam-
pled from classes E, I, and P are assumed (as an approximation)
to have the same antibody titer as the class R10. We simulate this
system until it reaches an equilibrium or stable oscillating behav-
ior, and we generate sample sets of size N every M months with
multinomial sampling, using e=0.05.
The probability that at time t, a serumsample st falls in titer class
i is:
P(st = i) =
⎧⎪⎨
⎪⎩
(1 − e)r1(t) + er2(t) i = 1
eri−1(t) + (1 − 2e)ri(t) + eri+1(t) 2 ≤ i ≤ 9
er9(t) + (1 − e)r10(t) i = 10,
(7)
where the ri(t) variables represent the proportions of individ-
uals in the population that have an antibody titer i at time t. When
performing inference with the reduced model, the probability is
P(st = i) =
⎧⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎩
(1 − e∗)r(1,4)(t) + er5(t) i = (1,4)
e∗r(1,4)(t) + (1 − 2e)r5(t) + er6(t) i = 5
eri−1(t) + (1 − 2e)ri(t) + eri+1(t) 6 ≤ i ≤ 9
er9(t) + (1 − e)r10(t) i = 10.
(8)
The misclassiﬁcation parameter e* is computed from the data using
number of serum samples inR
e∗ = e · 4
number of serum samples inR(1,4)
which gives us an approximation of the number of serum samples
in R1 through R4 whose antibody titer would be misclassiﬁed as R5.
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he full likelihood is deﬁned as the product across all samples, and
he log-likelihood is maximized over the parameters ˇ, A, and ϕ
sing a standard Nelder-Mead method (Nelder and Mead, 1965) in
atlab (Mathworks, Natick, MA). Conﬁdence intervals for param-
ter estimates are computed using likelihood proﬁles. Conﬁdence
ntervals are presented as medians over ten simulated data sets;
he median upper bound is taken and the median lower bound is
aken so that thepresented conﬁdence intervalmaynot correspond
o any particular simulation that was run.
.4. Assessing statistical identiﬁability
A key question when performing statistical inference on disease
ynamics using serological data is whether the three processes of
i) reinfection, (ii) post-infection antibody generation, and (iii) anti-
ody waning are statistically identiﬁable from one another. When
here is no seasonal forcing in the model (A=0), the dynamics
ettle to a non-oscillating endemic equilibrium – as any standard
usceptible-Infected-Recovered-Susceptible (SIRS) model would –
ut this endemic equilibrium will not be associated with a unique
et of parameters describing infection rate (ˇ and εi), antibody
eneration (pi), and antibody waning (i). This is a general prop-
rty of SIRS-like dynamical systems. As an example, in a standard
IRS model, we can always increase the waning rate and reduce
he transmission rate in a way that keeps the endemic equilib-
ium prevalence unchanged. Therefore, given a data set from a
eal-world SIRS-like epidemiological system, it may be difﬁcult or
mpossible to infer the values of the parameters ˇ, εi, pi, and i.
To illustrate this property and test its robustness to other fea-
ures of the system, we chose a parameter combination
0 = (ˇ, ε1, . . ., ε10, p1, . . ., p10, 1, . . ., 9) (9)
orresponding to an endemic equilibrium prevalence of 1.1%;0
orresponds to 30 parameter values. We then generated 100 ‘false’
arameter combinations {j}j=1,...,100 corresponding to the same
ndemic equilibrium, in order to determine if they can be distin-
uished from the true parameters0.
False parameter combinationsj were chosen according to the
ollowing procedure. First, we let ˇi =ˇ(1− εi) and chose ten ˇi
arameters uniformly on (0,1); we sorted and renumbered so that
10 was largest. Summing up the right-hand sides of the dynamical
quations for R1 through R10 in the general model (1), we obtain
P −
10∑
i=1
ˇiRˆiIˆ = 0
nd we rescale the ˇi so that the equation above is satisﬁed. We let
=ˇ10, which results in ε10 =0. Second, the 10 pi parameters were
lso chosen uniformly and within 10% of their true values, and they
ere normalized so that they summed to unity. The i parame-
ers were then obtained by solving the dynamical equations for Ri
ssuming endemic equilibrium. The parameters from this second
tep were accepted only if the i parameters satisﬁed i >j >0 for
ll i> j; if this condition was not met, the second step was repeated.
f the inferential system possesses statistical identiﬁability and no
ias, then the likelihood values of all thej combinations should
e strictly lower than the likelihood value of0.
Using the true parameters 0 and assuming no seasonality in
he dynamics (A=0), a data set X0 of titer measurements was gen-
rated by sampling from the dynamical system (1). Dynamics were
imulated until equilibrium, after which 200 recovered individ-
als were sampled at random every two months for four years to
enerate a data set X0 with 4800 total data points. Using Eq. (7),
he log-likelihood L(0|X0) was compared with the log-likelihoods
(j|X0) to determine if the true set of parameters0 could be dis-ics 12 (2015) 30–39
tinguished from false sets of parameters using likelihood methods.
In order to determine if low amplitudes – ones that cause dynam-
ics to oscillate around the endemic equilibrium – could improve
statistical identiﬁability, data sets XA for small positive values of A
were generated using the general model (1) and parameters 0.
Likelihood comparisons were also done using the data sets XA.
The analysis was repeated using system (1) with constraints
(2)–(4). A constrained parameter set
′0 = (ˇ,
,	, c,w) (10)
was chosen to correspond to an endemic equilibrium prevalence of
0.9%; the parameter set was′0 = (0.45,0.6,20.0,0.2,50). In this
case, false parameter combinations′j that correspond to the exact
endemic equilibrium of ′0 could not be found easily; therefore,
we chose false parameter combinations ′j that corresponded to
an endemic equilibrium close to the original one. First, we chose
	 ∈ U(15, 25), c ∈ U(0.18, 0.22), and w ∈ U(40,60). Second, we
optimized ˇ and 
 and checked to see if the L1-distance from the
false equilibrium to the true equilibrium was less than 0.5% of the
total population size. If this conditionwas notmet,we beganwith a
newrandomdrawof	, c, andw. Data setsX ′0 andX
′
A weregenerated
as above.
3. Results
3.1. Statistical identiﬁability
In general, it is clear that there is a statistical identiﬁability prob-
lem among the processes of antibody generation, antibody waning,
and reinfection. This is intuitive, as in many epidemiological mod-
els itmaybe expected that speedingupor slowingdownall of these
processesby thesame factormayresult innochangeor little change
in the system’s mean long-term dynamics. This is particularly true
if there is no seasonal forcing in the model.
When the model is seasonally forced, the shape of the sea-
sonal dynamics improves statistical identiﬁability among antibody
generation, antibody waning, and reinfection. We describe the
degree of statistical identiﬁability in our system by evaluating a
data set XA, generated with a set of true parameters0, and com-
puting the probability that XA could have been generated with
sets of false parameters {j}j=1,...,100. Simulating system (1) with
0 and amplitude A, we generate data sets XA and expect that
L(0|XA) > L(j|XA) for all j. However, Fig. 3A shows that when the
dynamics are not seasonally forced (A=0.0), the likelihoods of the
false parameter combination j are identical to that of the true
parameter combination0, making it impossible to estimate the
true parameters. As the amplitude is increased slightly, the like-
lihoods of the different scenarios j begin to differentiate as the
shapes of the oscillating trajectories will be dependent on whether
the individual processes of antibodywaning and reinfection are fast
or slow. Fig. 3B shows a similar behavior for model (1) simulated
with constraints (2)–(4). IncreasingA also improves statistical iden-
tiﬁability. Note that in this case, the false parameter combinations
′j weremore difﬁcult to generate thanj, and they are, in general,
quite close in parameter space to the true parameters′0. For this
reason, the likelihoods in Fig. 3B cluster together more closely than
the likelihoods in Fig. 3A.
Equilibrium prevalence in the above simulated data sets is
approximately 1.0%. A similar pattern of statistical identiﬁability
is seen as we vary ˇ and consider prevalences between 0.25%
and 0.65%. Figs. S1–S3 again show that statistical identiﬁability
improves as the amplitude A increases, but identiﬁability worsens
asˇ decreases, indicating that inference at very lowprevalence lev-
els may be difﬁcult. Thus, in epidemiological scenarios where there
are no seasonal dynamics, statistical inference using serological
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Fig. 3. Difference in log-likelihood values between the true parameter combination0 (used to generate data sets XA) and false parameter combinationsj that generate
similar dynamics. Panel A shows free parameter setsj as deﬁned by (9), and panel B shows constrained parameters sets
′
j as deﬁned by (10). Each point corresponds to
one of 100 false parameter combinations, and a negative number on the ordinate indicates that a particularj had lower log-likelihood than0. When the log-likelihood
difference is greater than ﬁve, no point is plotted; instead the number of points for which the log-likelihood difference is greater than ﬁve is indicated above the tick marks on
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s seasonal forcing increases, statistical identiﬁability improves.
ime series may be impossible; likewise, if seasonality is weak and
revalence levels are low, estimation of various epidemiological
rocesses will also be difﬁcult.
Understanding the relationships among antibody generation,
ntibody waning, and reinfection is crucial for knowing whether
particular serological data set can be used to infer properties of
isease dynamics. Ideally, these rateswould be estimated indepen-
ently using patient-level longitudinal data. For inﬂuenza, these
ata sets allow us to approximate the susceptibility reduction
arameter at 
 ≈0.6 (Hobson et al., 1972; Potter and Oxford, 1979;
ouch et al., 2012; Ng et al., 2013; Tsang et al., 2014). The formula-
ion of the reduced model (5) allows our simulation and inference
o be relatively insensitive to the antibody generation process
escribed by	. However, very fewgood estimates exist of thewan-
ng rate of inﬂuenza antibodies. In the section below, we evaluate
ur ability to perform inference on transmission and seasonality
arameters, given uncertainty in the rate of antibody waning.
.2. Estimation of transmission and seasonality parameters
In this section, we assume that w = 50 and that c varies in the
ange 0.2≤ c≤0.7. At the boundaries, this means that individuals’
ntibodies wane from a titer of 2560 (class R1) to a titer of 20 (class
8) in 1.8 years for the fast-waning scenario (c=0.2) and in 7.8
ears in the slow-waning scenario (c=0.7). We assume that 
 =0.6,
= 2.0, and that ˇ =0.3 corresponding to a basic reproductive ratio
f R0 =1.5. Seasonal amplitudes of A=0.1 and A=0.2 are used, to see
f we can statistically identify amplitudes lower than the expected
ange 0.3≤A≤0.6 for temperate areas (Truscott et al., 2011). The
iming of peak transmission is set arbitrarily to ϕ =. Using Eqs. (1)
ith constraints (2)–(4), we simulate our system until it reaches a
table oscillating behavior, and data sets are generated by sampling
individuals every two months for a duration of either three years
r four years. Inference is performed using the reduced model (5),
nd likelihood optimization is performed over the parameters ˇ, A,
nd ϕ.
Fig. 4 shows the conﬁdence intervals for our maximum-
ikelihood estimates of parameters ˇ, A, and ϕ when antibodyuted given eleven different data sets XA with different seasonal forcing amplitudes.
waning is fast (c=0.2; 1.8 years to lose protection). In general ˇ
is easy to estimate for sample sizes N≥100. This is to be expected,
because in a single cross-sectional set of serumsamples, ifwe know
the antibody waning rate, we should be able to estimate the level
of endemicity and thus the R0 value. The 95% conﬁdence intervals
for the amplitude parameter A do not include zero, indicating that
thepresenceof seasonality is detectable in anSSE studydesignwith
samples collected every twomonths for≥3 years. These conﬁdence
intervals are not symmetric about the true value, which results
from the irregular shape of the likelihood surface near A=0.0. The
maximum likelihood estimates of A appear to be biased slightly
upwards, but this is difﬁcult to know with certainty due to there
beingonly tenestimatesper sample size. The timeofpeak transmis-
sion (i.e. the phase ϕ of the forcing function) can also be reasonably
estimated. For N=150 and four years of data, the 95% conﬁdence
intervals for ϕ span a period covering 26 days (A=0.2) or 53 days
(A=0.1), indicating that the pattern of seasonal forcing is correctly
identiﬁed.Note thatwhenA is smaller,we are closer to the endemic
equilibrium and estimation of ˇ is easier; however, oscillations
are of lower magnitude, and hence estimation of A and ϕ is more
difﬁcult.
Estimating transmission intensity and identifying the transmis-
sion season is more difﬁcult when antibodies persist longer. With
a slightly slower rate of antibody waning (c=0.4; 3.3 years from
a titer of 2560 to a titer of 20), transmission and seasonality are
difﬁcult to estimate for small samples sizes. When seasonal forc-
ing is weak (A=0.1), the presence or absence of seasonality may be
impossible to infer with an SSE study design if the antibody wan-
ing process is slow. The bottom panels of Fig. 5 show that even for
large sample sizes, locating the timingof peak transmission (ϕ)may
be impossible; this also means that the corresponding conﬁdence
intervals for the amplitude A are epidemiologically meaningless as
the inference in this case is simply capturing noise in the system
and not any true seasonal behavior. If the true seasonal amplitude
is slightly larger (A=0.2),we canhope to estimate itwith large sam-
ple sizes (N≥200), and the transmission parameter ˇ should also
be estimated to within 20% of its true value. The conﬁdence inter-
vals computed in this section are not sensitive to the parameter 	
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Fig. 4. Conﬁdence intervals for parameters ˇ, A, and ϕ as a function of the sample size N, under a scenario of fast antibody waning (1.8 years to immune loss). Amplitudes
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ef A=0.2 (top row) and A=0.1 (bottom row) are used. Gray lines correspond to a t
he true parameter values. Data are simulated with system (1) and constraints (2)–
.0,w = 50, c = 0.2. Conﬁdence intervals shown are medians over ten simulated d
hen antibody waning is fast (Figs. S4 and S5); they are somewhat
ensitive to 	 when the antibody waning rate is slow (Figs. S6 and
7). The conﬁdence intervals in Figs. S8 and S9 show that if samples
re collected every four months (M=4), statistical identiﬁability is
onsiderably worse, even for fast antibody waning. Figs. S10–S17
resent all conﬁdence computed in this part of the analysis.In general, estimation of the seasonality parameters A and ϕ
s very sensitive to the rate of antibody waning. The reason for
his is that these parameters are estimated based on oscillations
n data collected on the recovered classes R1–R10, and these oscil-
ig. 5. Conﬁdence intervals for parameters ˇ, A, and ϕ as a function of the sample siz
mplitudes of A=0.2 (top row) and A=0.1 (bottom row) are used. Gray lines correspon
ines indicate the true parameter values. Data are simulated with system (1) and constr
re 
 = 0.6,	 = 2.0,w = 50, c = 0.4. Conﬁdence intervals shown are medians over ten s
stimate.year data set and black lines to a four-year data set, and the dashed lines indicate
d inference is performed with the reduced model (5). Parameters are 
 = 0.6,	 =
s, and the square on each line is the mean maximum-likelihood estimate.
lations are sensitive to the waning rate: a slow rate of waning will
cause individuals to stay in the R-classes longer and will dampen
the oscillations. This is a reminder that in a serology-based ﬁeld
study, observations are made on recovered or susceptible indi-
viduals, and oscillations in the recovered/susceptible population
behave differently than oscillations in the infected population.
Fig. 6 shows changes in these oscillations as the rate of anti-
body waning is slowed down. The left and middle columns of
Fig. 6 show the relative magnitude of oscillations to their long-
term average, both in the infected population (left column) and in
e N, under a scenario of moderate antibody waning (3.3 years to immune loss).
d to a three-year data set and black lines to a four-year data set, and the dashed
aints (2)–(4), and inference is performed with the reduced model (5). Parameters
imulated data sets, and the square on each line is the mean maximum-likelihood
D.N. Vinh, M.F. Boni / Epidemics 12 (2015) 30–39 37
Fig. 6. Effect of antibody waning on our ability to perform inference on seasonality parameters. Plots show equilibrium dynamics (left and middle columns) and likelihood
surfaces (right column) for ﬁve different rates of antibody waning; the c parameter and time to immune loss are shown on the left. The ﬁrst column of ﬁgures shows the
dynamics of I(t) relative to its long-term mean value, and the second column shows the dynamics of
∑
Ri(t) relative to its long-term mean value. As the rate of antibody
waning slows down, the relative magnitude of oscillations in the recovered classes decreases, making these oscillations more difﬁcult to detect. The right column shows
t ihood.
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the 95% conﬁdence region for A and ϕ, with the darker regions having highest likel
imulations and inference were performed with system (1) with constraints (2)–(4)
nference was performed on a 4-year data set with 200 samples collected every two
he recovered/susceptible population (middle column). The rela-
ive magnitude of oscillations in infected individuals is large and
nsensitive to changes in the rate of antibody waning. However,
scillations in the R classes are of smaller magnitude and dampen
ubstantially with slower waning. The likelihood surfaces on the
ight show that for A=0.1, the transmission season cannot be iden-
iﬁed reliably if immune loss takes longer than four years. Fig. S18
hows that statistical identiﬁability is improved when A=0.2.
. Discussion
If seroepidemiology is to become a useful tool for performing
nference on disease dynamics, we must understand which disease
rocesses have the largest effects onobservationsmade in serologi-
al studies. From the analyses presentedhere, it is apparent that the
ntibody waning rate is a crucial process that must be understood
nd measured precisely, in order to be able to perform accurate
nference from a serially sampled set of cross-sectional serum col-
ections. In addition, understanding antibody waning is also critical
or traditional seroepidemiological studies with a single cross-
ection. For infections whose antibody responses are expected to
ane, a cross-sectional sample only tells us the recent history of
he individuals in that sample, the degree of recency depending
n the rate of antibody waning. For diseases that confer life-long
mmunity, seroprevalence in a cross-sectional sample will corre-
pond to lifetime attack rate, but only if serological cutoffs are
hosen with care so that low-level antibody concentrations indica-
ive of past infection are counted as such. Knowing whether a basic
eroepidemiology study reports a disease’s attack rate over the past
everalmonthsorpast several years is critical for estimatingdisease
urden and public health planning.
Direct measurements of the antibody waning process are rare
Horsfall, 1940; Horsfall and Rickard, 1941; Buchy et al., 2010;
everson et al., 2012). One assumption we have made in this anal-
sis is that the antibody waning rate is not constant. We assume
hat there is a shorter transition time among the high-titer classesWhen antibody waning is slow (c>0.5), detecting the phase ϕ may be impossible.
eters used in the simulation were A=0.1, ϕ =, 
 =0.6, 	=2.0, ˇ =0.3, and w = 50.
ths.
(2560, 1280, . . .) than among the low-titer classes (80,40, . . .) and
that individuals maintain lower antibody titers for much longer
periods of time. We made this assumption based on the fact that
individuals are not typically observed to have high titers in many
cross-sectional studies. If this assumption holds true, it means that
the slowpart of thewaning processwill be difﬁcult tomeasure pre-
cisely, and not very useful for statistical inference as estimates will
almost certainly come with a high variance. In other words, given
an individual with a protective but low antibody titer, it would be
impossible to infer the date of that individual’s most recent infec-
tion. However, if we observe an individual in the fast-waning part
of the process, a high titer may be informative in estimating a time
window in the recent past when that individual experienced an
infection.
Finally, antibody waning will depend on age (Cauchemez et al.,
2012; Ng et al., 2013), which would also indicate that titer cut-
offs should be age-dependent. Current seroepidemiological studies
do not take this potential age-dependence into account, partially
because few studies are large enough, both in terms of numbers
of patients and duration of follow-up, to determine the nature
of this age-dependence. The waning rate will also be sensitive
to immunodominance relationships among strains, and speciﬁ-
cally to whether a host’s antibody proﬁle has arisen in response
to that host’s ﬁrst inﬂuenza infection. There will likely be other
causes of variation in the waning process, as is evidenced in most
cross-sectional studies by the presence of some individuals with
long-lived high titers that do not seem to be the result of original
antigenic sin. This is evident in the data used by Lessler et al. (2011,
2012) which show a noticeable minority of the study population
with high antibody titers to certain inﬂuenza strains that have been
out of circulation for ten or twenty years. Teasing out the effects
of age, strain, and original antigenic sin as contributors to varia-
tion in antibody titer is a major challenge for inﬂuenza serology.
Understanding the slower part of the antibody waning process will
be critical for studies aimed at long-term collection of serological
data.
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Two immediate beneﬁts of performing inference on serological
ime series are the ability to reconstruct completediseasedynamics
i.e. the dynamics of both symptomatic and asymptomatic indi-
iduals – and the avoidance of a reporting parameter. The study of
omplete disease dynamics is not something that has yet gained
igniﬁcant traction among ﬁeld epidemiologists. However, with
etter access to time-stratiﬁed serological collections (Wu et al.,
011, 2014; de Bruin et al., 2014) and new high-throughput sero-
ogical assays (Koopmans et al., 2011; Baas et al., 2013; Huijskens
t al., 2013), these types of studies may become more common.
ublic health beneﬁts of SSE-like study designs include the ability
o distinguish a large inﬂuenza epidemic from a severe inﬂuenza
pidemic. Additionally, we may be able to learn something about
he variation in the symptomatic or asymptomatic natures in the
pidemics dynamics of certain diseases. This is particularly impor-
ant for dengue virus as it is has been observed, by comparing case
eporting to serological data, that dengue epidemics can vary sub-
tantially in their symptomatic/asymptomatic ratio (Sangkawibha
t al., 1984).
For tropical inﬂuenza speciﬁcally, study designs based on sero-
ogical time series may hold a lot of promise as the dynamics of
ropical inﬂuenza are qualitatively different from those of temper-
te inﬂuenza epidemics. In tropical regions, as far as we know, it
s not possible to perform inﬂuenza surveillance using syndromic
ata alone, as case numbers for inﬂuenza-like illness (ILI) do not
eem to correlate well with case numbers for conﬁrmed inﬂuenza
Nguyen et al., 2009; Vongphrachanh et al., 2010), although more
tudy is needed in this area. Inferring dynamics from time series
f conﬁrmed inﬂuenza cases gives a clearer picture of inﬂuenza
ynamics, but even this type of surveillance may miss one of the
arger features of tropical inﬂuenza epidemiology, namely, that
ome regions in the tropics or sub-tropics may support year-round
irculation of viruses (Le et al., 2013; Nelson et al., 2014). We have
ot yet powered the SSE study design to determine how low of
level of persistent circulation we should be able to detect. The
nalyses presented here were all performed on epidemiological
cenarios with endemicity levels ranging from 0.2% to 1.1%; how-
ver, persistence levels during low-inﬂuenza periods may be even
ower than this. A second important feature of tropical inﬂuenza
hat needs to be understood is the regularity and amplitude of
easonality. Despite recent attempts to classify the seasonality of
nﬂuenza in tropical regions (Tamerius et al., 2013; Saha et al.,
014), it is still unclear whether a true inﬂuenza season exists in
any tropical countries. In addition, the shape and duration of the
eak transmission seasonhasnotbeendetermined formostpartsof
he world, and this transmission curve is not guaranteed to take on
he sinusoidal shape assumed in most seasonally-forced epidemic
odels. Thus, in addition to determining the presence or absence
f seasonal forcing, a part of the inferential procedure should be
ocused on determining its shape. If seasonal forcing does exist in
he tropics, it is likely to bemuchweaker than that observed in tem-
erate regions, and for this reason in thepresent studyweevaluated
ur ability to statistically identify low-level seasonality.
Given the importance of tropical inﬂuenza to global inﬂuenza
ynamics (Russell et al., 2008; Rambaut et al., 2008; Bedford et al.,
010; Bahl et al., 2011), and the possibility that persistence in trop-
cal regions may have an effect on the rate or ﬁxation probability
f antigenic changes in inﬂuenza (Boni et al., 2006; Russell et al.,
008;Rambautet al., 2008;Boni, 2008;AdamsandMcHardy, 2011),
t is critical that we continue gathering high-quality data that can
hed light on inﬂuenza’s persistence and seasonality patterns in
ropical countries. The serial seroepidemiology study design pre-
ented here is one method of gathering consistent and continuous
ample sets that will allow for reconstruction of complete disease
ynamics, and improve our understanding of the dynamic patterns
f inﬂuenza circulation in the tropics.ics 12 (2015) 30–39
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